

ECUADOR

Number of new cases

30 888

Number of deaths

16 158

Number of prevalent cases (5-year)

78 878


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	9 056 269	9 057 096	18 113 365
Incidence*			
Number of new cancer cases	13 890	16 998	30 888
Age-standardized incidence rate	143.3	163.5	152.7
Risk of developing cancer before the age of 75 years (cum. risk %)	14.1	15.9	15.0
Top 3 leading cancers (ranked by cases)**	Prostate Stomach Colorectum	Breast Cervix uteri Colorectum	Breast Prostate Stomach
Mortality*			
Number of cancer deaths	7 658	8 500	16 158
Age-standardized mortality rate	75.9	77.1	76.0
Risk of dying from cancer before the age of 75 years (cum. risk %)	7.0	7.7	7.3
Top 3 leading cancers (ranked by deaths)**	Prostate Stomach Lung	Breast Cervix uteri Stomach	Stomach Prostate Colorectum
Prevalence*			
5-year prevalent cases	32 488	46 390	78 878



Top 5 most frequent cancers**

Males




Total: 13 890

Rank	Cancer site	Number of cases	Percent
1st	Prostate	3 456	24.9%
2nd	Stomach	1 555	11.2%
3rd	Colorectum	1 167	8.4%
4th	NHL	765	5.5%
5th	Lung	664	4.8%
-	Others	6 283	45.2%

Number of new cases in 2022, males, all ages

Females




Total: 16 998

Rank	Cancer site	Number of cases	Percent
1st	Breast	3 903	23.0%
2nd	Cervix uteri	1 792	10.5%
3rd	Colorectum	1 364	8.0%
4th	Stomach	1 137	6.7%
5th	Thyroid	1 081	6.4%
-	Others	7 721	45.4%

Number of new cases in 2022, females, all ages

Both sexes



Total: 30 888

Rank	Cancer site	Number of cases	Percent
1st	Breast	3 903	12.6%
2nd	Prostate	3 456	11.2%
3rd	Stomach	2 692	8.7%
4th	Colorectum	2 531	8.2%
5th	Cervix uteri	1 792	5.8%
-	Others	16 514	53.5%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	3 903	1	12.6	4.2	1 154	4	7.1	1.2	12 401	15.7
Prostate	3 456	2	11.2	3.9	1 362	2	8.4	0.80	7 817	9.9
Stomach	2 692	3	8.7	1.4	2 194	1	13.6	1.0	3 709	4.7
Colorectum	2 531	4	8.2	1.4	1 283	3	7.9	0.60	6 944	8.8
Cervix uteri	1 792	5	5.8	1.8	939	7	5.8	0.94	5 456	6.9
NHL	1 463	6	4.7	0.82	740	9	4.6	0.39	4 426	5.6
Lung	1 348	7	4.4	0.67	1 145	5	7.1	0.55	1 690	2.1
Thyroid	1 290	8	4.2	0.66	216	17	1.3	0.11	4 444	5.6
Leukaemia	1 220	9	4.0	0.54	896	8	5.5	0.39	3 691	4.7
Liver	1 100	10	3.6	0.56	1 005	6	6.2	0.50	1 272	1.6
Corpus uteri	784	11	2.5	0.98	223	16	1.4	0.26	2 740	3.5
Pancreas	773	12	2.5	0.39	692	10	4.3	0.35	711	0.90
Bladder	692	13	2.2	0.35	258	13	1.6	0.09	1 942	2.5
Brain CNS	691	14	2.2	0.33	537	11	3.3	0.28	2 509	3.2
Kidney	583	15	1.9	0.34	241	14	1.5	0.14	1 735	2.2
Ovary	507	16	1.6	0.56	331	12	2.0	0.36	1 462	1.9
Melanoma	491	17	1.6	0.28	158	19	0.98	0.07	1 610	2.0
Testis	363	18	1.2	0.29	54	24	0.33	0.04	1 374	1.7
Multiple myeloma	276	19	0.89	0.16	241	14	1.5	0.14	747	0.95
Lip, oral cavity	244	20	0.79	0.13	110	21	0.68	0.05	692	0.88
Hodgkin lymphoma	224	21	0.73	0.10	71	23	0.44	0.03	752	0.95
Gallbladder	212	22	0.69	0.12	132	20	0.82	0.07	295	0.37
Oesophagus	192	23	0.62	0.09	174	18	1.1	0.08	222	0.28
Larynx	148	24	0.48	0.09	87	22	0.54	0.05	432	0.55
Penis	139	25	0.45	0.11	45	25	0.28	0.04	400	0.51
Oropharynx	86	26	0.28	0.05	39	26	0.24	0.02	234	0.30
Salivary glands	84	27	0.27	0.03	30	27	0.19	0.01	233	0.30
Vulva	73	28	0.24	0.08	28	28	0.17	0.02	192	0.24
Kaposi sarcoma	68	29	0.22	0.03	18	30	0.11	0.01	186	0.24
Nasopharynx	33	30	0.11	0.02	17	31	0.11	0.01	83	0.11
Vagina	30	31	0.10	0.02	9	32	0.06	0.01	80	0.10
Mesothelioma	26	32	0.08	0.02	22	29	0.14	0.01	33	0.04
All cancers	30 888	-	-	15.0	16 158	-	-	7.3	78 878	-
All cancers excl. NMSC	29 613	-	-	14.6	15 903	-	-	7.3	75 010	-

Data source and methods

Incidence



Country-specific data source: No data
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Mortality

Country-specific data source: National (WHO)
 Method: National rates projected to 2022

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

